← Back

Karyopharm Therapeutics Inc

Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company that discovers, develops, and commercializes drugs targeting nuclear export for cancer and other diseases in the United States. Its focus is on small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). The lead compound XPOVIO is approved in combination with bortezomib and dexamethasone for adult patients with multiple myeloma, with dexamethasone for relapsed or refractory multiple myeloma, and for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The company also develops selinexor for hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL, and eltanexor for other myeloproliferative neoplasms and TP53 wild-type solid tumors. It has license agreements with Menarini Group and Antengene Therapeutics, a distribution agreement with FORUS Therapeutics for XPOVIO, and a collaboration with Bristol Myers Squibb to evaluate mezigdomide in combination with selinexor in relapsed or refractory multiple myeloma. Karyopharm was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Country
Price · split & dividend adjusted
News & notes moving KPTI
Biotech & Genomic Medicine▲2

Karyopharm Plans August sNDA Filing for Myelofibrosis Combination

Karyopharm Therapeutics announced during its Second Quarter 2026 Financial Results Conference Call that it remains on track to submit a supplemental new drug application in August for selinexor in combination with ruxolitinib as a treatment for myelofibrosis. The company reported second quarter total revenue of $33.4 million, down from $37.9 million a year earlier, while U.S. XPOVIO net product revenue rose to $30.8 million from $29.7 million. Karyopharm ended the quarter with $65.4 million in cash, cash equivalents, restricted cash, and investments, and expects existing liquidity to fund operations into September 2026, with a $15.8 million principal payment due on its senior secured term loan on September 10, 2026. The company is actively evaluating financing opportunities and strategic alternatives, and reaffirmed full-year 2026 guidance of total revenue between $130 million and $150 million and combined R&D and SG&A expenses of $230 million to $245 million.
KPTI ▲
Biotech & Genomic Medicine
The Motley Fool·29dRead more →
Biotech & Genomic Medicine▼impact 4

Karyopharm's Phase 3 Endometrial Cancer Trial Misses Primary Endpoint

Karyopharm Therapeutics announced that its Phase 3 XPORT-EC-042 trial of Selinexor as maintenance therapy in TP53 wild-type advanced or recurrent endometrial cancer did not meet its primary endpoint of progression-free survival. In the modified intent-to-treat population of 236 patients, median progression-free survival was 12.75 months with Selinexor versus 7.43 months with placebo, a 5.3-month improvement that did not reach statistical significance. The safety profile was consistent with prior studies and no new safety signals were observed. Karyopharm plans to continue following patients for longer-term outcomes and will present full data at an upcoming medical meeting. The company's stock was trading at $2.40, down 65.71%.
KPTI ▼
Biotech & Genomic Medicine ▼
RTTNews·49dRead more →
© 2026 MarketDXAsset